New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareExenatide vs Follistatin 344

Exenatide vs Follistatin 344

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss AgonistsCognitive Enhancement
Exenatide
Anabolic & IGF
Follistatin 344
Summary
Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
Half-Life
~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
~24–36 hours
Admin Route
SubQ
SubQ, IM
Research
Typical Dose
5 mcg, titrate to 10 mcg
100 mcg
Frequency
Twice daily
Once daily
Key Benefits
  • Blood glucose control in type 2 diabetes
  • Weight loss (average 2–3 kg in clinical trials)
  • Once-weekly extended-release formulation available
  • Reduces appetite and food intake
  • Possible neuroprotective in Parkinson's disease (Phase II trials)
  • Reduces systemic inflammation
  • May protect pancreatic beta cells
  • Cardiovascular neutral or potentially protective
  • Inhibits myostatin — removes muscle growth ceiling
  • Significant increases in muscle mass and strength
  • Reduces fat mass
  • Promotes bone density
  • May stimulate hair follicle cycling
  • Anti-fibrotic effects in muscle tissue
  • Synergistic with IGF-1 and other anabolic peptides
Side Effects
  • Nausea (most common, especially initially)
  • Vomiting
  • Diarrhea
  • Headache
  • +4 more
  • Muscle soreness (from rapid hypertrophy)
  • Potential reproductive effects (activin inhibition)
  • Unknown long-term safety profile
  • Possible esophageal effects at high doses (animal data)
Stacks With